7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy

Pathophysiology & Hemodynamic Collapse

Acute pulmonary embolism (PE) is an emergent, life-threatening manifestation of venous thromboembolism (VTE). Physical obstruction of the pulmonary arterial bed combined with neurohumoral pulmonary vasoconstriction (mediated by thromboxane A2 and serotonin released from activated platelets) causes an abrupt surge in pulmonary vascular resistance (PVR). Because the thin-walled right ventricle (RV) cannot acutely generate peak systolic pressures exceeding 40 to 50 mmHg, this sudden increase in afterload triggers acute right ventricular dilation, increased RV wall tension, and RV myocyte ischemia.

                         SPIRAL OF RIGHT VENTRICULAR COLLAPSE
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Acute Pulmonary Arterial Obstruction ──► Abrupt Surge in PVR & RV Afterload │
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         │
                                         ▼
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Acute RV Dilation & Myocardial Wall Tension ──► RV Ischemia & Decreased RV EF│
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         │
                                         ▼
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Interventricular Septal Flattening / Shift ──► Impaired Left Ventricular EDV│
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         │
                                         ▼
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Precipitous Drop in Systemic Cardiac Output ──► Hypotension & Cardiogenic Shock│
  │ (Decreased Aortic Root Perfusion ──► Worsens Right Coronary Artery Ischemia) │
  └─────────────────────────────────────────────────────────────────────────────┘

As the dilated right ventricle shifts the interventricular septum toward the left (septal flattening or "D-shaped" left ventricle on echocardiography), left ventricular end-diastolic volume (preload) is severely compromised. This leads to a precipitous drop in systemic cardiac output, systemic hypotension, decreased coronary artery perfusion pressure, worsening RV ischemia, and fatal obstructive shock.

---

Risk Stratification Framework: ESC Tiers and the 2026 AHA/ACC Categories

Modern emergency management of acute PE is dictated not by anatomical clot burden, but by clinical risk stratification of early mortality. The European Society of Cardiology (ESC) tiers below remain the most widely taught.

In February 2026 the AHA and ACC, with eight other societies, published their first dedicated acute PE guideline (Creager et al.). It introduces AHA/ACC Acute PE Clinical Categories A through E, with subcategories:

The 2026 guideline also recommends PE response teams, LMWH over UFH when initial parenteral anticoagulation is needed, DOACs over vitamin K antagonists for patients eligible for oral therapy, and extended anticoagulation after a first unprovoked PE or with a persistent risk factor. Systemic thrombolysis remains recommended for high-risk PE. For Categories E1–2 with acceptable bleeding risk, thrombolysis plus anticoagulation is reasonable over anticoagulation alone, and it may be considered for D1–2.

Clinical Risk Scoring Tools

• Simplified Pulmonary Embolism Severity Index (sPESI): Evaluates 6 variables (1 point each): Age >80 years, history of cancer, chronic cardiopulmonary disease, heart rate ≥110 beats/min, systolic BP <100 mmHg, and arterial oxygen saturation <90%. A score of 0 identifies low-risk patients (30-day mortality 1.0%), whereas a score of ≥1 denotes intermediate-to-high risk (30-day mortality 10.9%).

---

Systemic Thrombolytic Pharmacotherapy

Systemic thrombolysis accelerates clot dissolution, rapidly lowers pulmonary artery pressure and PVR, reverses RV dilation, and restores systemic cardiac output in patients with acute obstructive shock.

Alteplase Dosing Protocols

1. Standard Full-Dose Regimen (Hemodynamically Unstable / Massive PE):
   • Alteplase (rtPA): 100 mg IV continuous infusion administered over 2 hours.
   • Administration Nuance: Usually administered as a 10 mg IV bolus over 1 to 2 minutes followed by 90 mg IV infused over the remainder of the 2 hours.
2. Accelerated / Emergency Regimen (Cardiac Arrest or Impending Arrest):
   • Alteplase: 50 mg IV push administered over 15 minutes (or 0.6 mg/kg up to a maximum of 50 mg).
   • Cardiac Arrest Context: In PEA cardiac arrest secondary to suspected or confirmed massive PE, administration of a 50 mg IV bolus should be accompanied by prolonged CPR (European Resuscitation Council guidance suggests considering 60 to 90 minutes) to allow the fibrinolytic agent to circulate, penetrate the occlusive thrombus, and restore pulmonary perfusion.
3. Tenecteplase (TNK-tPA) Alternative:
   • Administered as a single weight-based IV bolus over 5 to 10 seconds: <60 kg: 30 mg; 60 to <70 kg: 35 mg; 70 to <80 kg: 40 mg; 80 to <90 kg: 45 mg; ≥90 kg: 50 mg. (Widely utilized in the PEITHO trial).

Thrombolytic Contraindications Matrix

---

The Landmark PEITHO Trial & The Intermediate-Risk Dilemma

One of the most heavily tested concepts on the BCEMP examination is the controversial role of systemic thrombolytic therapy in normotensive intermediate-high risk (submassive) PE.

• Study Design: The PEITHO (Pulmonary Embolism Thrombolysis) trial randomized 1,006 normotensive patients with intermediate-high risk PE (exhibiting both RV dysfunction on echo/CT and positive troponin I/T) to weight-based single-bolus tenecteplase plus unfractionated heparin versus placebo plus unfractionated heparin.
• Primary Composite Outcome: Fibrinolytic therapy significantly reduced the primary composite endpoint of all-cause mortality or hemodynamic collapse within 7 days (2.6% vs 5.6%; p = 0.02).
• The Critical Caveat: This benefit was driven entirely by a reduction in hemodynamic collapse (1.6% vs 5.0%). There was no statistically significant difference in 30-day all-cause mortality (2.4% vs 3.2%; p = 0.42).
• Hemorrhagic Harm: Systemic fibrinolysis resulted in a dramatic, catastrophic increase in major extracranial bleeding (6.3% vs 1.2%; p <0.001) and hemorrhagic stroke / intracranial hemorrhage (2.0% vs 0.2%; p = 0.003), predominantly in patients aged >75 years.
• Guideline Consensus: Routine systemic thrombolytic therapy is NOT recommended for intermediate-risk PE. Instead, intermediate-high risk patients should receive therapeutic parenteral anticoagulation and be admitted to an ICU or step-down unit with close monitoring. Full-dose or half-dose "rescue" thrombolysis is initiated only if the patient develops overt hemodynamic decompensation (SBP <90 mmHg, signs of shock).

---

Advanced Interventional Therapies: CDT & Mechanical Thrombectomy

When systemic thrombolysis carries prohibitive bleeding risk or fails to restore hemodynamics, catheter-based interventional therapies offer targeted pulmonary reperfusion.

                      PULMONARY REPERFUSION MODALITIES
  ┌───────────────────────────────────────────────────────────────────────────┐
  │ Systemic Thrombolysis: Alteplase 100 mg IV over 2h (Rapid, High Bleed Risk)│
  ├───────────────────────────────────────────────────────────────────────────┤
  │ Catheter-Directed Thrombolysis (CDT): Ultrasound-assisted (EKOS) or pigtail│
  │  • Low-dose Alteplase: 0.5–1.0 mg/h per catheter over 12–24h (Max 24 mg)   │
  │  • Dramatically reduces major bleeding (ICH <0.5%) vs systemic lytics     │
  ├───────────────────────────────────────────────────────────────────────────┤
  │ Percutaneous Mechanical Thrombectomy: Large-bore aspiration (FlowTriever)  │
  │  • Rapid mechanical clot extraction without any thrombolytic drug exposure │
  │  • Drug of choice when thrombolytics are absolutely contraindicated       │
  ├───────────────────────────────────────────────────────────────────────────┤
  │ Surgical Pulmonary Embolectomy: Cardiopulmonary bypass clot extraction    │
  │  • Indicated for massive PE with failed lysis, thrombus-in-transit, or PFO│
  └───────────────────────────────────────────────────────────────────────────┘

Catheter-Directed Thrombolysis (CDT)

• Technique: Infusion catheters (e.g., standard multi-sidehole or ultrasound-accelerated EKOS catheters) are positioned directly into the pulmonary arterial thrombus via femoral or internal jugular access.
• Pharmacotherapy: Ultra-low-dose alteplase infused at 0.5 to 1.0 mg/hour per catheter (typically 1.0 mg/h for unilateral PE, or 0.5 mg/h per catheter for bilateral PE) over 12 to 24 hours. Total delivered alteplase dose ranges from 12 to 24 mg (compared to 100 mg for systemic lysis).
• Safety Profile: Clinical trials (ULTIMA, SEATTLE II) demonstrated significant reductions in RV/LV diameter ratios and pulmonary artery pressures with an intracranial hemorrhage rate of <0.5%.

Percutaneous Mechanical Thrombectomy

• Devices: Large-bore aspiration systems (e.g., Inari FlowTriever, Penumbra Indigo CAT8/Lightning).
• Clinical Utility: Enables rapid clot extraction without administering any thrombolytic drug. It is the premier reperfusion strategy for patients with massive or deteriorating intermediate-high risk PE who harbor absolute contraindications to fibrinolytic therapy (e.g., recent intracranial hemorrhage, major surgery within 3 weeks).

---

Parenteral Anticoagulation Protocols

Parenteral anticoagulation must be initiated immediately upon suspicion or confirmation of acute PE to halt thrombus propagation and prevent secondary thromboembolism.

Unfractionated Heparin (UFH)

• Role in High-Risk PE: The 2026 AHA/ACC guideline prefers LMWH over UFH for most patients needing initial parenteral anticoagulation. UFH is still chosen when thrombolysis or a procedure is imminent, in hemodynamically unstable patients, and in severe renal impairment (CrCl <30 mL/min), because it is short-acting and fully reversible.
• Pharmacological Advantages: Short half-life (60 to 90 minutes), reticuloendothelial clearance independent of renal excretion, and complete, instantaneous reversibility with protamine sulfate (1 mg per 100 units of heparin administered in the preceding 2 hours, maximum 50 mg).
• Weight-Based Dosing Protocol:
  • IV Bolus: 80 units/kg IV (maximum 10,000 units).
  • Initial Infusion: 18 units/kg/hour (maximum 2,000 units/hour).
  • Therapeutic Monitoring: Titrated to institutional anti-Xa levels (0.3 to 0.7 IU/mL) or activated partial thromboplastin time (aPTT 1.5 to 2.5 times control, typically 60 to 80 seconds) measured every 6 hours until stable.
• Management During Systemic Thrombolysis:
  • When initiating systemic alteplase (100 mg over 2 hours), the UFH infusion is generally held during the 2-hour thrombolytic infusion to minimize catastrophic bleeding risk, or infused without an initial bolus.
  • Following completion of alteplase, UFH should be resumed without a bolus once the aPTT falls below 2 times normal control (<80 seconds).

Low-Molecular-Weight Heparin (Enoxaparin)

• Dosing: 1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily.
• Renal Adjustment: If CrCl <30 mL/min, reduce dosing to 1 mg/kg SC once every 24 hours (or preferably switch to UFH due to unpredictable accumulation of anti-Xa activity and heightened bleeding).
• Monitoring: Routine anti-Xa monitoring is unnecessary; in extreme obesity (>140 kg or BMI >40 kg/m²), peak anti-Xa measured 4 hours post-dose (target 0.6 to 1.0 IU/mL for q12h dosing) ensures therapeutic adequacy.

Fondaparinux

• Mechanism: Synthetic pentasaccharide that selectively binds antithrombin III to inhibit factor Xa.
• Weight-Tiered Dosing:
  • Body weight <50 kg: 5 mg SC once daily.
  • Body weight 50 to 100 kg: 7.5 mg SC once daily.
  • Body weight >100 kg: 10 mg SC once daily.
• Contraindications: Absolutely contraindicated if CrCl <30 mL/min due to 100% renal elimination and lack of a specific reversal agent.

---

Transition to Oral DOACs & Special Populations

Direct oral anticoagulants (DOACs) are recommended over vitamin K antagonists (warfarin) for the initial and long-term treatment of VTE in eligible patients due to superior safety, lower intracranial bleeding rates, and operational ease.

                         ORAL DOAC INITIATION REGIMENS
  ┌───────────────────────────────────────────────────────────────────────────┐
  │ SINGLE-DRUG ORAL REGIMENS (NO PARENTERAL LEAD-IN REQUIRED)                │
  │  • Apixaban: 10 mg PO BID for 7 days ──► 5 mg PO BID maintenance          │
  │  • Rivaroxaban: 15 mg PO BID with food for 21 days ──► 20 mg PO daily food│
  ├───────────────────────────────────────────────────────────────────────────┤
  │ PARENTERAL LEAD-IN REQUIRED (MINIMUM 5–10 DAYS PARENTERAL HEPARIN/LMWH)   │
  │  • Dabigatran: 150 mg PO BID (after 5–10 days parenteral anticoagulation) │
  │  • Edoxaban: 60 mg PO daily (after 5–10 days parenteral anticoagulation)  │
  │    (Reduce Edoxaban to 30 mg daily if CrCl 15–50 mL/min or weight ≤60 kg) │
  └───────────────────────────────────────────────────────────────────────────┘

Special Clinical Populations & Nuances

1. Antiphospholipid Syndrome (APS): In patients with confirmed triple-positive APS (positive lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein I antibodies), DOACs are strictly contraindicated. The landmark TRAPS trial demonstrated an unacceptably high rate of recurrent arterial thromboembolic events with rivaroxaban compared to warfarin. Patients must receive parenteral heparin bridging to warfarin targeting an INR of 2.0 to 3.0.
2. Extreme Obesity (BMI ≥40 kg/m² or Weight >120 kg): Guidance from the International Society on Thrombosis and Haemostasis (ISTH) endorses standard-dose apixaban or rivaroxaban as appropriate options. For patients with BMI >50 kg/m² or those who have undergone malabsorptive bariatric surgery, LMWH or warfarin remains preferred, or peak and trough anti-Xa drug levels should be evaluated.
3. Cancer-Associated Thrombosis (CAT): Oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) or LMWH are recommended. In patients with active gastrointestinal or genitourinary mucosal malignancies, apixaban or LMWH is preferred over rivaroxaban/edoxaban due to lower mucosal bleeding rates.
4. Pregnancy: DOACs cross the placenta and are strictly contraindicated. Warfarin is teratogenic (causing fetal warfarin embryopathy). Therapeutic weight-adjusted LMWH is the drug of choice throughout pregnancy and the immediate postpartum period.